During the last session, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)’s traded shares were 0.56 million, with the beta value of the company hitting 0.64. At the end of the trading day, the stock’s price was $42.12, reflecting an intraday loss of -0.40% or -$0.17. The 52-week high for the CRNX share is $49.58, that puts it down -17.71 from that peak though still a striking 62.58% gain since the share price plummeted to a 52-week low of $15.76. The company’s market capitalization is $3.28B, and the average trade volume was 801.67K shares over the past three months.
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) trade information
Crinetics Pharmaceuticals Inc (CRNX) registered a -0.40% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.40% in intraday trading to $42.12, hitting a weekly high. The stock’s 5-day price performance is -1.98%, and it has moved by -5.20% in 30 days. Based on these gigs, the overall price performance for the year is 125.72%.
Crinetics Pharmaceuticals Inc (CRNX) estimates and forecasts
Statistics show that Crinetics Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Crinetics Pharmaceuticals Inc (CRNX) shares have gone up 48.00% during the last six months, with a year-to-date growth rate less than the industry average at 9.49% against 10.40. In the rating firms’ projections, revenue will decrease -46.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 260k as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 810k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.68M and 988k respectively. In this case, analysts expect current quarter sales to shrink by -90.30% and then drop by -18.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -10.59%. While earnings are projected to return 13.21% in 2024.
CRNX Dividends
Crinetics Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
